Effects of the dual peroxisome proliferator–activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes

Background Insulin-resistant states, including type 2 diabetes (T2D) and prediabetes, are associated with elevated cardiovascular (CV) risk. Aleglitazar is a dual peroxisome proliferator–activated receptor α/γ agonist with favorable insulin-sensitizing and glucose-lowering actions, favorable effects...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2015-07, Vol.170 (1), p.117-122
Hauptverfasser:	Erdmann, Erland, MD, Califf, Robert, MD, Gerstein, Hertzel C., MD, Malmberg, Klas, MD, Ruilope, Luis, MD, Schwartz, Gregory G., MD, Wedel, Hans, MD, Volz, Dietmar, MD, Ditmarsch, Marc, MD, Svensson, Anders, MD, Bengus, Monica, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Cardiovascular Cardiovascular Diseases - complications Cardiovascular Diseases - prevention & control Cerebrovascular Disorders - complications Cholesterol Coronary Disease - complications Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Double-Blind Method Early Termination of Clinical Trials Female Glycated Hemoglobin A - metabolism Heart attacks Humans Hypoglycemia - chemically induced Hypoglycemic Agents - therapeutic use Male Metabolic disorders Middle Aged Mortality Myalgia - chemically induced Myocardial Infarction - complications Myocardial Infarction - prevention & control Myositis - chemically induced Oxazoles - therapeutic use Peripheral Arterial Disease - complications PPAR alpha - agonists PPAR gamma - agonists Prediabetic State - complications Prediabetic State - drug therapy Prediabetic State - metabolism Stroke - complications Stroke - prevention & control Thiophenes - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background Insulin-resistant states, including type 2 diabetes (T2D) and prediabetes, are associated with elevated cardiovascular (CV) risk. Aleglitazar is a dual peroxisome proliferator–activated receptor α/γ agonist with favorable insulin-sensitizing and glucose-lowering actions, favorable effects on blood lipids, and an acceptable safety profile in short-time studies. Therefore, it was hypothesized that aleglitazar would reduce CV morbidity and mortality in patients with T2D mellitus and prediabetes (defined as glycosylated hemoglobin ≥5.7% to
ISSN:	0002-8703 1097-6744
DOI:	10.1016/j.ahj.2015.03.021